Harbor MedTech Inc.
This article was originally published in Start Up
Executive Summary
Rising rates of obesity and diabetes, coupled with America's aging population, have accelerated the demand for chronic wound care products to treat such prevalent conditions as diabetic foot ulcers, venous ulcers and pressure ulcers. To capitalize on this growing market, Harbor MedTech Inc. has developed NeuvoCell, the first candidate from its promising collagen cross-linking technology. Once inserted into the wound, NeuvoCell restarts and supports the healing process from start to finish. The xenograft also contains agents to prevent infections.